WO2000025808A8 - Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists - Google Patents

Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists

Info

Publication number
WO2000025808A8
WO2000025808A8 PCT/US1999/025501 US9925501W WO0025808A8 WO 2000025808 A8 WO2000025808 A8 WO 2000025808A8 US 9925501 W US9925501 W US 9925501W WO 0025808 A8 WO0025808 A8 WO 0025808A8
Authority
WO
WIPO (PCT)
Prior art keywords
differentiation
psgl
cytotoxic
antagonists
inhibition
Prior art date
Application number
PCT/US1999/025501
Other languages
French (fr)
Other versions
WO2000025808A1 (en
WO2000025808A9 (en
Inventor
Narasimhaswamy Manjunath
Von Andrian Ulrich Hans
Original Assignee
Genetics Inst
Cbr Lab Inc
Narasimhaswamy Manjunath
Von Andrian Ulrich Hans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst, Cbr Lab Inc, Narasimhaswamy Manjunath, Von Andrian Ulrich Hans filed Critical Genetics Inst
Priority to EP99964950A priority Critical patent/EP1131084A4/en
Priority to CA002347119A priority patent/CA2347119A1/en
Priority to JP2000579247A priority patent/JP2002528513A/en
Priority to BR9914957-5A priority patent/BR9914957A/en
Priority to IL14271799A priority patent/IL142717A0/en
Priority to MXPA01004310A priority patent/MXPA01004310A/en
Priority to AU30971/00A priority patent/AU774419C/en
Publication of WO2000025808A1 publication Critical patent/WO2000025808A1/en
Publication of WO2000025808A8 publication Critical patent/WO2000025808A8/en
Publication of WO2000025808A9 publication Critical patent/WO2000025808A9/en
Priority to AU2004214516A priority patent/AU2004214516A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Methods are disclosed for inhibiting the differentiation of an activated T-cell into a cytotoxic lymphocyte in a mammalian subject, comprising administering to a subject a therapeutically effective amount of a PSGL antagonist.
PCT/US1999/025501 1998-10-30 1999-10-29 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists WO2000025808A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP99964950A EP1131084A4 (en) 1998-10-30 1999-10-29 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
CA002347119A CA2347119A1 (en) 1998-10-30 1999-10-29 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
JP2000579247A JP2002528513A (en) 1998-10-30 1999-10-29 Inhibition of cytotoxic T-cell differentiation by P-selectin ligand (PSGL) antagonists
BR9914957-5A BR9914957A (en) 1998-10-30 1999-10-29 Inhibition of cytotoxic t cells by selectin-p ligand antagonists (psgl)
IL14271799A IL142717A0 (en) 1998-10-30 1999-10-29 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
MXPA01004310A MXPA01004310A (en) 1998-10-30 1999-10-29 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists.
AU30971/00A AU774419C (en) 1998-10-30 1999-10-29 Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists
AU2004214516A AU2004214516A1 (en) 1998-10-30 2004-09-22 Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10631598P 1998-10-30 1998-10-30
US60/106,315 1998-10-30

Publications (3)

Publication Number Publication Date
WO2000025808A1 WO2000025808A1 (en) 2000-05-11
WO2000025808A8 true WO2000025808A8 (en) 2000-10-26
WO2000025808A9 WO2000025808A9 (en) 2001-07-19

Family

ID=22310736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/025501 WO2000025808A1 (en) 1998-10-30 1999-10-29 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists

Country Status (11)

Country Link
US (1) US20020058034A1 (en)
EP (1) EP1131084A4 (en)
JP (1) JP2002528513A (en)
CN (1) CN1342085A (en)
AU (2) AU774419C (en)
BR (1) BR9914957A (en)
CA (1) CA2347119A1 (en)
IL (1) IL142717A0 (en)
MX (1) MXPA01004310A (en)
NZ (1) NZ528610A (en)
WO (1) WO2000025808A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
DE60231016D1 (en) * 2001-06-05 2009-03-12 Genetics Inst Llc Process for the purification of strongly anionic proteins
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
CA2483476A1 (en) * 2002-04-22 2003-10-30 Absorber, Ab Fusion polypeptides and methods for inhibiting microbial adhesion
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
KR20050059001A (en) * 2002-07-01 2005-06-17 사비언트 파마슈티컬즈 인코퍼레이티드 Compositions and methods for therapeutic treatment
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
AU2003263764A1 (en) * 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
US7459523B2 (en) * 2003-11-12 2008-12-02 Wisconsin Alumni Research Foundation Equine P-selectin glycoprotein ligand-1 and uses thereof
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
KR20120085921A (en) 2004-05-11 2012-08-01 압제노믹스 코오페라티에프 유.에이. T-cell death-inducing epitopes
JP2008541760A (en) * 2005-05-31 2008-11-27 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ Regulation of T cell recruitment
US20070298034A9 (en) * 2005-12-09 2007-12-27 Angela Widom Sulfotyrosine specific antibodies and uses therefor
PT3494986T (en) 2008-08-14 2020-07-14 Acceleron Pharma Inc Gdf traps for use to treat anemia
CA2838952C (en) 2011-06-13 2020-11-24 Stefan Bassarab Anti-psgl-1 antibodies and uses thereof
CN106659784B (en) * 2014-07-08 2022-03-29 桑福德伯纳姆医学研究所 PSGL-1 modulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585103A (en) * 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
US5747036A (en) * 1991-08-28 1998-05-05 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
JPH08502886A (en) * 1992-10-23 1996-04-02 ジェネティックス・インスティテュート・インコーポレイテッド Novel P-selectin ligand protein
US6277975B1 (en) * 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
WO1994011498A1 (en) * 1992-11-16 1994-05-26 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for p-selectin and methods of use thereof
US5614615A (en) * 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5659018A (en) * 1995-08-01 1997-08-19 Genetics Institute, Inc. Mocarhagin, a cobra venom protease, and therapeutic uses thereof
AU723262B2 (en) * 1995-08-03 2000-08-24 Board Of Regents Of The University Of Oklahoma, The Peptide and O-glycan inhibitors of selectin mediated inflammation
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy

Also Published As

Publication number Publication date
AU774419C (en) 2005-03-03
CN1342085A (en) 2002-03-27
NZ528610A (en) 2005-03-24
AU774419B2 (en) 2004-06-24
JP2002528513A (en) 2002-09-03
IL142717A0 (en) 2002-03-10
WO2000025808A1 (en) 2000-05-11
MXPA01004310A (en) 2003-06-06
AU2004214516A1 (en) 2004-10-14
EP1131084A4 (en) 2001-12-19
WO2000025808A9 (en) 2001-07-19
CA2347119A1 (en) 2000-05-11
EP1131084A1 (en) 2001-09-12
US20020058034A1 (en) 2002-05-16
AU3097100A (en) 2000-05-22
BR9914957A (en) 2001-07-24

Similar Documents

Publication Publication Date Title
WO2000025808A8 (en) Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
AU2272097A (en) Drug delivery compositions suitable for intravenous injection
AU4357693A (en) Device for detecting amount done by excavator/loader
AU5534490A (en) Fuel filler pipe seal
AU9648098A (en) Adenosine a3 receptor antagonists
ZA962248B (en) Nanususpensions for intravenous administration
AU5701794A (en) A method for preparing pharmaceutical compositions through ultrasonic means
MX9605023A (en) Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
HU9200458D0 (en) Soluble, one-chained t-cell receptors
AU8912898A (en) Methods for inhibiting detrimental side-effects due to gnrh or gnrh agonist administration
AU4086099A (en) Fuel injector
HUP0103852A3 (en) Container for intravenous administration
AU6175398A (en) New delivery system for administering dentin-hypersensitivity-ameliorating compositions
AU4623293A (en) Pipe cutting machine
HK1036011A1 (en) Pharmaceutical composition for injection based on paracetamol
AUPQ984500A0 (en) Multi-additive injection system for aviation fuel
AU2660199A (en) Method for ultrasound triggered drug delivery
AU3632297A (en) Spirocyclic dopamine receptor subtype ligands
WO2001009119A3 (en) Chemokine receptor antagonists
HUP9600333A3 (en) Azole derivatives as adhesive receptor antagonists, pharmaceutical compositions containing the same and process for their preparation
AU6979494A (en) Azacyclic-heterocyclic compounds as angiotensin ii receptor antagonists
BG103196A (en) Crystalline pharmaceutical product
BG103986A (en) Derivatives of pyrrolidinecarboxylic acids as endotheline antagonists
AU9794698A (en) Enhanced immunogenic cell populations prepared using h2 receptor antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99815217.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 142717

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2347119

Country of ref document: CA

Ref document number: 2347119

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 579247

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004310

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 511836

Country of ref document: NZ

Ref document number: 30971/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999964950

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1 AND 8-23, DESCRIPTION, REPLACED BY NEW PAGES 1 AND 8-23; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999964950

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 30971/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999964950

Country of ref document: EP